The Essentials for Secondary Stroke Prevention

Slides:

Advertisements

Similar presentations

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

Advertisements

Addressing the Challenges in Primary and Secondary Stroke Prevention

Covering the Bases in Cardioversion

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

Oral Anticoagulants and Reversal Agents

Novel oral anticoagulants in comparison with warfarin

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Atrial Fibrillation and PCI

Anticoagulants in Interventional Cardiology:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

NOACs In Long-term VTE Treatment: A State Of The Art Review

US Guidelines US Guidelines Low-risk Patients.

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Access to NOAC Therapy:

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

A New Era for NOACs:.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Up to Date on Which NOAC for Which Patient

New Perspectives in AF and PCI: Implications for the Practicing Physician.

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Oral Anticoagulants in AFa,b A Brief History.

Selecting NOACs for High-Risk Patients

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

How to Adjust Anticoagulant Dosing

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Treatment Options to Consider

NOACS: Emerging data in ACS/IHD

Efficacy and Safety of Edoxaban in Patients With AF and HF

AF and PCI in Practice.

Access to NOAC Therapy:

Antithrombotic Protection in CAD and HF

Adherence in SPAF: Measures to Improve Care

What Anticoagulant Registries Are Revealing

A Better Solution For Cancer Patients With VTE?

Reversal Strategies for VKA: Truths and Misconceptions

Oral Anticoagulation in AF

Dos and Don’ts for High-Risk Elderly Patients With AF

Atrial Fibrillation.

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Taking the "Cryptogenic" Out of Cryptogenic Stroke

NOACs in AF: Consequences of Underdosing and NonAdherence

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Identifying High-Risk AF Patients

CAD/PAD in Primary Care

What You Didn't Know About AF and Renal Dysfunction

A Case Challenge.

New European Anticoagulant Approvals Will They Affect Practical Guidance?

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Managing Pulmonary Embolism Posthospital Discharge

Program Goals Background: Anticoagulation in Patients With VTE.

NOACs in AF: Consequences of Underdosing and NonAdherence

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Taking the "Cryptogenic" Out of Cryptogenic Stroke

5 Good Minutes on Atrial Fibrillation-related Stroke

NOACs and Reversal Agents

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

How to Adjust Anticoagulant Dosing

Uptitration of Medications in HF: Start Low but Aim High and Stay High

Real-World Data in Cardiology: Focus on Atrial Fibrillation

Extraordinary Cases in Stroke Prevention

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

The Essentials for Secondary Stroke Prevention

Program Goals

Patient Case

Goals for Anticoagulation Therapy in AF

OAC Is More Effective Than Aspirin for Secondary Stroke Prevention in AF

RE-LY Subgroup Analysis Time to Stroke or SE in Patients With/Without Previous Stroke or TIA

ROCKET AF Subgroup Analysis Time to Stroke or SE in Patients With/Without Previous Stroke or TIA

ARISTOTLE Subgroup Analysis Time to Stroke or SE in Patients With/Without Previous Stroke or TIA

ENGAGE AF-TIMI 48 Subgroup Analysis Patient Characteristics

Outcomes With Edoxaban vs Warfarin in Patients With Previous Cerebrovascular Events

ICH Rate With Edoxaban vs Warfarin in Patients With Previous Cerebrovascular Events

Meta-Analysis in Secondary Stroke Prevention Stroke or SE

Meta-Analysis in Secondary Stroke Prevention Hemorrhagic Stroke

NOAC Meta-Analysis in Secondary Stroke Prevention: Conclusions

2016 ESC Guidelines for the Management of AF

Initiation or Resumption of Anticoagulation Depends on Severity of Stroke*

ESC Guidelines Use of Aspirin for Secondary Stroke Prevention

Choosing a Particular OAC and Dose for Stroke Prevention in Individual Patients With NVAF

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)